First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

Abstract

In patients with WT-KRAS mCRC and LLD, both first-line Pmab-FOLFOX4 and Pmab-FOLFIRI resulted in high ORR and ETS, allowing potentially curative resection. No significant differences in efficacy were observed between the two regimens. (clinicaltrials.gov:NCT00885885).

Efficacy and safety of anti‐EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild‐type metastatic colorectal cancer: A meta‐analysis

“…The current guidelines recommend anti‐EGFR MoAbs combined with FOLFOX or FOLFIRI chemotherapy as the first‐line treatment for mCRC, while chemotherapy partner choice is a controversial issue. Although adding anti‐EGFR MoAbs to either FOLFOX or FOLFIRI chemotherapy has demonstrated significant improvement of ORR, PFS, and OS when compared with chemotherapy regimens alone, the benefits between the two combined regimens showed no significant difference, and the choice of FOLFOX or FOLFIRI regimen depends on the expected therapeutic toxicity.…”

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential

“…With conventional systemic (SYS) chemotherapy alone, the median survival for patients with unresectable CRLM is approximately 30 months . In patients whose tumors are RAS‐wild‐type, a higher median survival of over three years has been reported . Conversion to complete resection with SYS chemotherapy has been reported, but conversion rates are low, ranging from 13% to 27% .…”

“…[17][18][19][20][21][22][23][24] In patients whose tumors are RAS-wild-type, a higher median survival of over three years has been reported. [25][26][27][28] Conversion to complete resection with SYS chemotherapy has been reported, but conversion rates are low, ranging from 13% to 27%. 6,7,12,29 Furthermore, reports of conversion are methodologically flawed due to lacking or vague definitions of resectability.…”

Systemic treatment for metastatic colorectal cancer in the era of precision medicine

“…Given the uncertainty of resectability in this group of patients, the integration of bevacizumab is still considered appropriate. Other phase II and III studies evaluated the addition of anti‐EGFR therapy to chemotherapy in KRAS and RAS wild‐type patients and have shown a consistent improvement in RR, resection rate, and a favorable OS (Table ) . These data should be interpreted while considering the predictive impact of sidedness on response and outcome.…”

“…Other phase II and III studies evaluated the addition of anti-EGFR therapy to chemotherapy in KRAS and RAS wild-type patients and have shown a consistent improvement in RR, resection rate, and a favorable OS (Table 9). [90][91][92][93][94][95][96] These data should be interpreted while considering the predictive impact of sidedness on response and outcome. We believe that anti-EGFR therapy should only be considered as part of conversion therapy in RAS wild-type left colonic tumors.…”